高级检索
当前位置: 首页 > 详情页

MicroRNA-27a alleviates IL-1 beta-induced inflammatory response and articular cartilage degradation via TLR4/NF-kappa B signaling pathway in articular chondrocytes

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shanghai Jiao Tong Univ, Dept Orthoped Surg, Tongren Hosp, Sch Med, 1111 Xianxia Rd, Shanghai 200336, Peoples R China
出处:
ISSN:

关键词: Osteoarthritis MicroRNA-27a Inflammatory response Articular cartilage degradation TLR4/NF-kappa B signaling pathway

摘要:
Osteoarthritis (OA) is a common disease of the articular cartilage, and inflammatory response and articular cartilage degradation have been implicated in the pathogenesis of OA. In recent years, microRNAs (miRNAs) have been potentially involved in the pathogenesis of OA. However, little is known about the role of miRNAs in the inflammatory response and articular cartilage degradation in OA and the underlying molecular mechanism. In the present study, we analyze miRNA profiles in the articular tissues from OA patients using microarray. miR27a has attracted considerable interest for its suppressive effects on inflammation. Subsequently, the expression levels of miR-27a were validated in the articular tissues of OA patients and IL-I beta-stimulated chondrocytes. Using this IL-I beta-induced chondrocyte injury model, we found that upregulation of miR-27a suppressed articular cartilage degradation, the reactive oxygen species (ROS) production and inflammatory response as reflected by reductions in pro-inflammatory cytokines, including interleukin (IL)-6 and IL-8 and tumor necrosis factor (TNF)-alpha. Moreover, toll-like receptor 4 (TLR4), one upstream molecule of NF-kappa B signaling pathway, was identified as a direct target of miR-27a in chondrocytes. Furthermore, it was demonstrated that overexpression of TLR4 by pcDNA-TLR4 markedly abrogated the inhibitory effects of miR-27a on the inflammatory response and the degeneration of articular cartilage induced by IL-1 beta. Our findings suggest that miR-27a may be considered as a potential therapeutic target in the treatment of OA.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 3 区 免疫学 3 区 药学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 免疫学 2 区 药学
JCR分区:
出版当年[2017]版:
Q2 PHARMACOLOGY & PHARMACY Q3 IMMUNOLOGY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Shanghai Jiao Tong Univ, Dept Orthoped Surg, Tongren Hosp, Sch Med, 1111 Xianxia Rd, Shanghai 200336, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Shanghai Jiao Tong Univ, Dept Orthoped Surg, Tongren Hosp, Sch Med, 1111 Xianxia Rd, Shanghai 200336, Peoples R China [*1]Department of Orthopedic Surgery Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No.1111 Xianxia Road, Changning District, Shanghai 200336, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)